Fluocinolone Acetonide Topical Solution Usp, 0.01%

Prescription

Noms de marque : Fluocinolone Acetonide Topical Solution USP, 0.01%

Forme Pharmaceutique

Topical

Voie d'Administration

TOPICAL

Fabricant

Bryant Ranch Prepack

About This Medication

DESCRIPTION Fluocinolone Acetonide Topical Solution, 0.01% is intended for topical administration. The active component is the corticosteroid ﬂuocinolone acetonide, which has the chemical name pregna-1, 4-diene-3, 20-dione, 6, 9-diﬂuoro-11, 21-dihydroxy-16, 17-[(1-methylethylidene) bis (oxy)]-, (6α, 11β, 16α)-. It has the following chemical structure: Fluocinolone Acetonide Topical Solution USP, 0.01% contains ﬂuocinolone acetonide 0.1 mg/mL in a water-washable base of anhydrous citric acid and propylene glycol.

Principes Actifs

Ingrédient	Dosage
Fluocinolone Acetonide	-

Indications et Utilisation

INDICATIONS AND USAGE Fluocinolone Acetonide Topical Solution USP, 0.01% is indicated for the relief of the inﬂammatory and pruritic manifestations of corticosteroid-responsive dermatoses.

Posologie et Administration

DOSAGE AND ADMINISTRATION Fluocinolone Acetonide Topical Solution USP, 0.01% is generally applied to the affected area as a thin film from two to four times daily depending on the severity of the condition. In hairy sites, the hair should be parted to allow direct contact with the lesion. Occlusive dressings may be used for the management of psoriasis or recalcitrant conditions. If an infection develops, the use of occlusive dressings should be discontinued and appropriate antimicrobial therapy instituted.

Side Effects Overview

ADVERSE REACTIONS The following local adverse reactions are reported infrequently with topical corticosteroids, but may occur more frequently with the use of occlusive dressings. These reactions are listed in an approximate decreasing order of occurrence: Burning Perioral dermatitis Itching Allergic contact dermatitis Irritation Maceration of the skin Dryness Secondary infection Folliculitis Skin atrophy Hypertrichosis Striae Acneiform eruptions Miliaria Hypopigmentation

Contre-indications

CONTRAINDICATIONS Topical corticosteroids are contraindicated in those patients with a history of hypersensitivity to any of the components of the preparation.

Frequently Asked Questions

INDICATIONS AND USAGE Fluocinolone Acetonide Topical Solution USP, 0.01% is indicated for the relief of the inﬂammatory and pruritic manifestations of corticosteroid-responsive dermatoses.

DOSAGE AND ADMINISTRATION Fluocinolone Acetonide Topical Solution USP, 0.01% is generally applied to the affected area as a thin film from two to four times daily depending on the severity of the condition. In hairy sites, the hair should be parted to allow direct contact with the lesion. Occlusive dressings may be used for the management of psoriasis or recalcitrant conditions. If an infection develops, the use of occlusive dressings should be discontinued and appropriate antimicrobial therapy instituted.

CONTRAINDICATIONS Topical corticosteroids are contraindicated in those patients with a history of hypersensitivity to any of the components of the preparation.

Fluocinolone Acetonide Topical Solution Usp, 0.01% is a prescription medication. You will need a valid prescription from a licensed healthcare provider.

References & Data Sources

• DailyMed — Fluocinolone Acetonide Topical Solution Usp, 0.01% drug label (National Library of Medicine)
• openFDA — Fluocinolone Acetonide Topical Solution Usp, 0.01% label data (U.S. Food & Drug Administration)
• RxNorm — RXCUI 1191310 (NLM Normalized Drug Names)
• NDC Directory — Fluocinolone Acetonide Topical Solution Usp, 0.01% (FDA National Drug Code)

Avertissement Médical

Les informations sur cette page sont destinées à des fins éducatives uniquement et ne doivent pas être utilisées en remplacement d'un avis médical professionnel, d'un diagnostic ou d'un traitement.

Consultez toujours votre médecin ou tout autre professionnel de santé qualifié pour toute question relative à une condition médicale ou à un médicament.

Sources des données : DailyMed (NLM), openFDA, MFDS